- Novartis was testing the drug in a large clinical trial as a potential tool against heart disease.
- The trial failure marks a setback for Novartis’s cardiovascular drug pipeline.
Quotes
“Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.”